Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H10N2O2S |
Molecular Weight | 186.231 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC1=CC=C(C=C1)S(N)(=O)=O
InChI
InChIKey=TYMRLRRVMHJFTF-UHFFFAOYSA-N
InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)
Molecular Formula | C7H10N2O2S |
Molecular Weight | 186.231 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/4948236 | http://www.rxlist.com/sulfamylon-cream-drug.htm | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=570ce479-d902-4394-bbae-41dfe16c5485
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/4948236 | http://www.rxlist.com/sulfamylon-cream-drug.htm | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=570ce479-d902-4394-bbae-41dfe16c5485
Mafenide is a sulfonamide-type medication used as an antibiotic. It is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds. Mafenide is not antagonized by pABA, serum, pus or tissue exudates, and there is no correlation between bacterial sensitivities to mafenide and to the sulfonamides. A single case of bone marrow depression and a single case of an acute attack of porphyria have been reported following therapy with mafenide acetate. Fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with mafenide acetate. Other adverse reactions are: pain or burning sensation, rash and pruritis, erythema, skin maceration from prolonged wet dressings, facial edema, swelling, hives, blisters, eosinophilia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22974493 |
25.0 µM [Ki] | ||
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22974493 |
17.1 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SULFAMYLON Approved UseSULFAMYLON® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds. Launch Date-2.95488E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
197 μg/mL |
77 g single, topical dose: 77 g route of administration: Topical experiment type: SINGLE co-administered: |
MAFENIDE blood | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
26 μg/mL |
14 g single, topical dose: 14 g route of administration: Topical experiment type: SINGLE co-administered: |
MAFENIDE blood | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
10 μg/mL |
14 g single, topical dose: 14 g route of administration: Topical experiment type: SINGLE co-administered: |
CARZENIDE blood | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
340 μg/mL |
77 g single, topical dose: 77 g route of administration: Topical experiment type: SINGLE co-administered: |
CARZENIDE blood | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
11.2 % single, topical Highest studied dose Dose: 11.2 % Route: topical Route: single Dose: 11.2 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
Other AEs: Pain, Pain... Other AEs: Pain (grade 3, 58%) Sources: Page: p.1447Pain (grade 2, 33%) Pain (grade 1, 8%) |
5 % single, topical Recommended Dose: 5 % Route: topical Route: single Dose: 5 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
Other AEs: Pain, Pain... Other AEs: Pain (grade 3, 12.5%) Sources: Page: p.1447Pain (grade 2, 33%) Pain (grade 1, 46%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pain | grade 1, 8% | 11.2 % single, topical Highest studied dose Dose: 11.2 % Route: topical Route: single Dose: 11.2 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
Pain | grade 2, 33% | 11.2 % single, topical Highest studied dose Dose: 11.2 % Route: topical Route: single Dose: 11.2 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
Pain | grade 3, 58% | 11.2 % single, topical Highest studied dose Dose: 11.2 % Route: topical Route: single Dose: 11.2 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
Pain | grade 1, 46% | 5 % single, topical Recommended Dose: 5 % Route: topical Route: single Dose: 5 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
Pain | grade 2, 33% | 5 % single, topical Recommended Dose: 5 % Route: topical Route: single Dose: 5 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
Pain | grade 3, 12.5% | 5 % single, topical Recommended Dose: 5 % Route: topical Route: single Dose: 5 % Sources: Page: p.1447 |
unhealthy, 9+ n = 24 Health Status: unhealthy Condition: burns Age Group: 9+ Sex: M+F Population Size: 24 Sources: Page: p.1447 |
PubMed
Title | Date | PubMed |
---|---|---|
Antifungal activity of Ag(I) and Zn(II) complexes of aminobenzolamide (5-sulfanilylamido-1,3,4-thiadiazole-2-sulfonamide) derivatives. | 2000 |
|
The use of 5% mafenide acetate solution in the postgraft treatment of necrotizing fasciitis. | 2001 Jan-Feb |
|
Does the addition of nystatin to 5% mafenide acetate and genitourinary irrigant solutions interfere with their antimicrobial activity? Assessment by two topical antimicrobial test assay systems. | 2001 Jul-Aug |
|
Topical mafenide hydrochloride aqueous spray in initial management of massive contaminated wounds with devitalized tissue. | 2001 Jul-Sep |
|
Off-label drug use in WOC nursing: issues related to use of mafenide acetate to treat infected chronic wounds. | 2001 Sep |
|
An in vivo comparison of topical agents on wound repair. | 2001 Sep 1 |
|
Carbonic anhydrase inhibitors: synthesis of water soluble sulfonamides incorporating a 4-sulfamoylphenylmethylthiourea scaffold, with potent intraocular pressure lowering properties. | 2002 Oct |
|
Dressings for burn injury in a military conflict--change of practice based on current evidence. | 2002 Sep |
|
Using mafenide acetate in acute and chronic wounds. | 2002 Sep |
|
Comparative evaluation of topical antiseptic/antimicrobial treatment on aspects of wound repair in the porcine model. | 2002 Sep |
|
Silver-sulfadiazine eschar pigmentation mimics invasive wound infection: a case report. | 2003 May-Jun |
|
Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective. | 2004 Apr |
|
Exploring the binding mode of semicarbazide-sensitive amine oxidase/VAP-1: identification of novel substrates with insulin-like activity. | 2004 Sep 23 |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Hypochlorous acid as a potential wound care agent: part I. Stabilized hypochlorous acid: a component of the inorganic armamentarium of innate immunity. | 2007 Apr 11 |
|
Seven years' experience with Integra as a reconstructive tool. | 2007 Jan-Feb |
|
Controlling methicillin resistant Staphyloccocus aureus and Pseudomonas aeruginosa wound infections with a novel biomaterial. | 2007 Jul-Aug |
|
Comparative evaluation of silver-containing antimicrobial dressings and drugs. | 2007 Jun |
|
The search for an ideal temporary skin substitute: AWBAT. | 2009 |
|
Highly antibiotic-resistant Acinetobacter baumannii clinical isolates are killed by the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG). | 2009 Apr |
|
A prospective double-blinded comparative analysis of framycetin and silver sulphadiazine as topical agents for burns: a pilot study. | 2009 Aug |
|
The antimicrobial effect of acetic acid--an alternative to common local antiseptics? | 2009 Aug |
|
Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? | 2009 Jan-Feb |
|
Nanofibers offer alternative ways to the treatment of skin infections. | 2010 |
|
Detecting extracellular carbonic anhydrase activity using membrane inlet mass spectrometry. | 2010 Aug |
|
Activity of topical antimicrobial agents against multidrug-resistant bacteria recovered from burn patients. | 2010 Dec |
|
A review of the applications of the hydrofiber dressing with silver (Aquacel Ag) in wound care. | 2010 Feb 2 |
|
Special considerations in paediatric burn patients. | 2010 Sep |
|
Fungal infections in burns: Diagnosis and management. | 2010 Sep |
|
Fluid management in major burn injuries. | 2010 Sep |
|
Downstream gene activation of the receptor ALX by the agonist annexin A1. | 2010 Sep 17 |
|
The diversity of wound presentation associated with freon contact frostbite injury. | 2010 Sep-Oct |
|
Comparison between topical honey and mafenide acetate in treatment of burn wounds. | 2011 Sep 30 |
Sample Use Guides
The grafted area should be covered with one layer of fine mesh gauze. An eight-ply burn dressing should be cut to the size of the graft and wetted with Mafenide 5% solution using an irrigation syringe and/or irrigation tubing until leaking is noticeable.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4948236
The action of mafenide is primarily bacteriostatic and it has been demonstrated to be active in vitro in concentrations of 5 mg/ml or less against a variety of Gram-positive and Gram-negative organisms. Ps. aeruginosa is the most sensitive; with 32 of 41 strains the minimum inhibitory concentration (MIC) was 0.2 to 1 mg/ml and with the remaining 9 strains the MIC was 2 to 5 mg/ml. In other studies the mean MIC was 0.31 mg/ml (range 0.075 to 5 mg/ml) for 55 strains of Ps. aeruginosa isolated from clinical material (Thompson et al., 1969) and 1.25 mg/ml for 7 strains of Ps. Aeruginosa.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:21:41 UTC 2023
by
admin
on
Fri Dec 15 15:21:41 UTC 2023
|
Record UNII |
58447S8P4L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175512
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
||
|
WHO-VATC |
QD06BA53
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
||
|
NDF-RT |
N0000175512
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
||
|
NDF-RT |
N0000175511
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
||
|
WHO-VATC |
QD06BA03
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
||
|
WHO-ATC |
D06BA03
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
||
|
NDF-RT |
N0000175512
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3998
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
1624
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
100000081737
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
DB06795
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
CHEMBL419
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
2393
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
D008272
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
DTXSID6047860
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
C61819
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
6572
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
34632
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
205-326-9
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
m6982
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
138-39-6
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
SUB08633MIG
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
58447S8P4L
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
58447S8P4L
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY | |||
|
MAFENIDE
Created by
admin on Fri Dec 15 15:21:41 UTC 2023 , Edited by admin on Fri Dec 15 15:21:41 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |